Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14834704 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2L3MBTL1ALDH1A1HTTKMT2A | |
| SCHEMBL3080948 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2L3MBTL1ALDH1A1HTTKMT2A | |
| SCHEMBL4703205 | 0.95 | SMN1; SMN2 (0.37) | SMN1; SMN2L3MBTL1ALDH1A1HTTKMT2A | |
| SCHEMBL14834486 | 0.89 | SMN1; SMN2 (0.40) | SMN1; SMN2L3MBTL1ALDH1A1KMT2AGAA | |
| SCHEMBL14834460 | 0.89 | SMN1; SMN2 (0.40) | SMN1; SMN2L3MBTL1ALDH1A1KMT2AGAA | |
| SCHEMBL3966132 | 0.89 | SMN1; SMN2 (0.40) | SMN1; SMN2L3MBTL1ALDH1A1KMT2AGAA | |
| SCHEMBL14834692 | 0.86 | LMNA (0.35) | SMN1; SMN2L3MBTL1DRD2 | |
| SCHEMBL14834396 | 0.86 | LMNA (0.35) | SMN1; SMN2L3MBTL1DRD2 | |
| SCHEMBL11972105 | 0.80 | OPRM1 (0.36) | SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL15049918 | 0.80 | OPRM1 (0.36) | SMN1; SMN2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576537-B1 | 2-AMINO-PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF JNK | HOFFMANN LA ROCHE (CH) | 2016-03-16 | — | — | EP | claimed |
| US-8642601-B2 | Inhibitors of JNK | ROCHE PALO ALTO LLC (US) | 2014-02-04 | — | — | US | claimed |
| EP-2576537-A1 | 2 -AMINO- PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF JNK | F.HOFFMANN-LA ROCHE AG (CH) | 2013-04-10 | — | — | EP | claimed |
| WO-2011151358-A1 | 2 -AMINO- PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF JNK | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-08 | — | — | WO | claimed |
| US-20110301171-A1 | Inhibitors of JNK | ARZENO HUMBERTO BARTOLOME (US) | 2011-12-08 | — | — | US | claimed |
| EP-2576537-B1 | 2-AMINO-PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF JNK | HOFFMANN LA ROCHE (CH) | 2016-03-16 | — | — | EP | disclosed |
| US-8642601-B2 | Inhibitors of JNK | ROCHE PALO ALTO LLC (US) | 2014-02-04 | — | — | US | disclosed |
| US-20110301171-A1 | Inhibitors of JNK | ARZENO HUMBERTO BARTOLOME (US) | 2011-12-08 | — | — | US | disclosed |
| EP-1303485-A1 | PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| US-6541638-B2 | (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction | HOFFMAN-LA ROCHE INC. | 2003-04-01 | — | — | US | disclosed |
| US-20020049243-A1 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. | 2002-04-25 | — | — | US | disclosed |
| WO-2002006222-A1 | PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301171-A1 | Inhibitors of JNK | MAPK9, MAP3K9, MAPK1 | SMN1; SMN2 3209/4885L3MBTL1 1546/4885ALDH1A1 4409/4885 |
| US-20020049243-A1 | Pyrrolidine derivatives | PREP, PEPD, DNPEP | SMN1; SMN2 3409/4885L3MBTL1 3514/4885ALDH1A1 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.